Podcasts about Biostatistics

The World Health Organization defines health equity as a public health concept describing equity of access to health resources for genetic, socio-environmental, and economic determinants of health, varying according to individuals, families, and social or societal groups. Concerns about data equity have surfaced, which may result in many populations, including those in rural areas with disabilities, experiencing homelessness or living in low and middle-income regions of the world, being underrepresented in health data sets. This can lead to biased findings and suboptimal health outcomes for certain subgroups, which is the focus of this episode of Stats+Stories with guest Bhramar Mukherjee. Dr. Bhramar Mukherjee is the inaugural Senior Associate Dean of Public Health Data Science and Data Equity and the Anna M. R. Lauder Professor of Biostatistics, as well as Professor of Epidemiology and of Statistics and Data Science at Yale University. Among her many honors, she was elected to the US National Academy of Medicine in 2022.

External control arms are becoming increasingly important in drug development, but creating valid comparisons requires more than matching patient populations. In this episode, I speak with Ben Ackerman, Director of Real-World Biostatistics at GSK, about one of the most overlooked challenges in external control arm studies: endpoint bias. We discuss why differences in how outcomes are measured can influence study results, what researchers should consider when designing studies, and how the field is evolving to address these challenges. If you work with real-world evidence, causal inference, or innovative clinical trial designs, this episode offers valuable insights into improving the credibility and transparency of external control arm analyses.

In this episode of ACM ByteCast, Rashmi Mohan hosts 2025 ACM Fellow Cynthia Rudin, the Gilbert, Louis, and Edward Lehrman Distinguished Professor of Computer Science, Electrical and Computer Engineering, Statistical Science, Mathematics, and Biostatistics and Bioinformatics at Duke University, where she leads the Interpretable Machine Learning Lab. Her lab, which seeks to design predictive ML models that people can understand, focuses on areas including healthcare, criminal justice, and energy reliability. Among her honors, she has received the Squirrel Award for Artificial Intelligence from the Association for the Advancement of Artificial Intelligence (AAAI), as well as the IJCAI John McCarthy Award. Rudin was recently named an ACM Fellow for contributions to and leadership in interpretable machine learning and societal applications. In the interview, Cynthia clarifies the crucial distinction between "interpretable" and “explainable" AI and makes the argument that true interpretability is foundational to trustworthy, ethical AI. She shares her extensive field experience collaborating with Con Edison engineers on power grid maintenance, neurologists on medical diagnostics, and the Cambridge Police Department on crime series detection, countering the widespread industry myth that AI performance must be sacrificed for transparency. She describes an innovative paradigm her lab developed to solve the "interaction bottleneck" between data scientists and domain experts, leveraging "Rashomon sets" to generate millions of equally accurate models simultaneously, using human-computer interaction (HCI) tools to create visual, encyclopedia-like interfaces.

Did you know that glyphosate is the most commonly used herbicide in the world, and because of its ubiquitous use, glyphosate can be found in most of our bodies? Join Food Sleuth Radio host and Registered Dietitian, Melinda Hemmelgarn for her conversation with Lianne Sheppard, PhD, Professor in the Departments of Environmental and Occupational Health Sciences, and Biostatistics at the University of WA-Seattle. Sheppard discusses highlights and conclusions from the Seattle Glyphosate Symposium, and the risks from long term, low-level exposure. She also discusses why EPA registration of a pesticide does not mean that the pesticide is safe. To see the pesticides (insecticides, herbicides, fungicides and rodenticides) used in your part of the country, see the USGS maps of pesticide use: https://water.usgs.gov/nawqa/pnsp/usage/maps/compound_listing.php Related Websites:   Glyphosate symposium: https://deohs.washington.edu/sgs/statement

Small islands generally did far better during the pandemic than bigger (and often richer) countries with more complex health systems. In this episode, Emily and Matt ask: what have been the longer-term effects of Covid-19 more than five years on? Have lessons have been learned for the next shock? Where can we see both improvements and things to worry about in health provision and outcomes? We welcome two global public health experts for our “Explainer”. Sophie Harman tells us why we should worry about not only the decline of multilateral health governance, but also what might be replacing it. Simon Rushton talks us through some of the longer-term effects of the pandemic on the Global South. Then, in the Big Picture, we are joined by Roannie Ng Shiu from Samoa and Aviane Auguste from St Lucia to learn why SIDS did relatively so well in the pandemic but why more prosaic health challenges – from measles to dengue and non-communicable diseases like diabetes – are of greater immediate concern. Finally, in no stupid questions, Matt and Emily ask whether small size and islandness are actually secret weapons in helping SIDS to achieve better health outcomes. LISTENER SURVEY: To help us make Small Islands, Big Picture even better, we've put together a short audience survey and would love your input. You can find the survey at this link and your feedback will help us shape future episodes, topics, and guests. If you have a moment, please fill it out: it only takes a couple of minutes would mean a lot to us. Thanks for listening and supporting the show! Featuring:Emily Wilkinson (host) | RESI Director and Principal Research Fellow at ODI GlobalMatthew Bishop (host) | RESI Director and Senior Lecturer at the University of SheffieldSophie Harman | Professor of International Politics, Queen Mary, University of LondonSimon Rushton | Professor of International Politics, University of SheffieldRoannie Ng Shiu | Director, Institute for Pacific and Global Health, University of AucklandAvianne Auguste | Assistant Professor, Epidemiology, Biostatistics and Occupational health, McGill University Resources:Programme page | Resilient and Sustainable Islands Initiative (RESI)Sophie's profile | Professor Sophie HarmanSophie's film | PiliSophie's book | Sick of it: the global fight for women's healthSimon's profile | Professor Simon RushtonSimon's award | ESRC Impact Prize: Improbable DialoguesSimon & Sophie's recent Lancet article | Global health partnerships for a post-2030 agendaRoannie's profile | Dr Roannie Ng ShiuRoannie's Lancet article | The 2024 small island developing states report of the Lancet Countdown on health and climate changeAviane's profile | Dr Aviane AugusteA public lecture by Aviane | Improving health outcomes in small islandsAn important Lancet piece | SIDS standing together on NCDs and mental health Hosted on Acast. See acast.com/privacy for more information.

In this episode, we explore the power of the 4+1 Program at NYU GPH, an accelerated pathway that allows students to earn both their undergraduate and master's degrees in just five years. We are joined by Nehanda Akili, an MS Biostatistics student, and Anthony Escamilla, an MPH Community Health Science and Practice student and pre-PA track junior, to discuss how this program provides a competitive edge for future healthcare leaders. Nehanda shares her journey from NYU Gallatin's individualized study—where she concentrated on the intersection of fascism and public health—to mastering data science and R coding. She discusses the importance of GPH's flexibility, which allowed her to balance 18-credit semesters while serving as President of the Black Women's Health Collective. Anthony, an EMT and psychology major, explains how the program allows him to bridge the gap between social theory and clinical practice. He highlights the financial benefits of the "plus one" year and how GPH's location in the NYC epicenter offers valuable opportunities for culturally competent public health intervention. From navigating the application process to utilizing the ecosystem of faculty support, Nehanda and Anthony offer a roadmap for students looking to maximize their time at NYU. This conversation highlights how the 4+1 Program turns academic ambition into real-world impact. To learn more about the NYU School of Global Public Health, and how our innovative programs are training the next generation of public health leaders, visit http://www.publichealth.nyu.edu.

What lies behind a career dedicated to improving healthcare through data?From growing up in Bosnia and Herzegovina during wartime to building a successful career in Sweden, Aldina Pivodic's story is one of resilience, courage and determination.Today, she is CEO and founder of APNC, a fast-growing consultancy at the forefront of medical statistics and life science research.With an MSc in Mathematics and a PhD from Sahlgrenska Academy, Aldina Pivodic has spent over two decades working across academia, pharma and medtech - applying advanced statistical methods in medical research and developing and validating algorithms for clinical decision support tools, to improve patient outcomes.In this episode, we talk resilience, ambition and the role of statistics in shaping the future of healthcare.Learn more about APNC Sweden AB here.

Zak Mir talks to Dr Jim Millen, Non-Executive Chairman, Physiomics, regarding recent progress at the mathematical modelling, data science and biostatistics company, and issues regarding the forthcoming requisitioned meeting.What Physiomics actually doesPhysiomics is a specialised life sciences consultancy that works with companies developing new drugs. At its core, the business helps drug developers make better decisions about how they design and run studies.The company operates across two main areas. Mathematical modelling to support the design of preclinical and clinical trials, with a particular focus on oncology, though not limited to cancer treatment. Biostatistics, covering the statistical design of trials, reporting, planning, and regulatory interactions around trial outcomes. That combination matters. Drug development is expensive, time-consuming and high risk. The more rigorously a company can model likely outcomes and build trials correctly from a statistical standpoint, the better its chances of generating meaningful data and navigating the regulatory process successfully.In simple terms, Physiomics is there to help clients ask the right questions before they spend serious money answering them.Why mathematical modelling and biostatistics matter in drug developmentIt is worth pausing on this, because companies like Physiomics can easily be misunderstood as niche technical advisers operating in the background.In reality, their work sits close to the heart of pharmaceutical decision-making. A poorly designed trial can waste years. A weak statistical framework can undermine otherwise promising results. And if preclinical and clinical plans are not thought through properly, the cost of fixing mistakes later can be enormous.That is why the company's two-pronged offering is significant: Modelling helps shape trial design and strategy Biostatistics helps ensure studies are set up, analysed and reported in a way regulators and stakeholders can rely on For drug developers, especially in challenging therapeutic areas such as oncology, that expertise can be highly valuable.Signs the business is turning a cornerOne of the most important points to emerge recently is that Physiomics appears to be at a positive inflection point.The company has reported its highest-ever first-half income, up by around 50% on the comparable prior period. Market expectations are also for the business to deliver its highest-ever full-year income, and management has indicated that it believes the company remains on track to achieve that.That is not a trivial development. In a market where many life sciences businesses have struggled for funding and momentum, a services company tied to that ecosystem inevitably feels the pressure too.The logic is straightforward: Physiomics serves companies developing drugs If those companies are short of capital, they become more cautious about spending That pressure filters through to specialist service providers By that measure, the last few years have not been easy. Management has been candid in saying that the wider life sciences market, especially over the past five years, has created a difficult backdrop. So when stronger income figures start to come through, that is naturally seen as evidence that the business may be emerging from a tougher period.The phrase used was that the company feels like it is "turning a corner", and the recent numbers are being presented as proof of that shift.The wider market backdrop for life sciences consultanciesTo understand why recent progress matters, it helps to appreciate the commercial reality of a business like Physiomics.This is not a company that develops and sells its own blockbuster drug. It provides highly specialised consultancy services to clients who are themselves trying to advance drug programmes. That means demand for Physiomics' expertise is linked to confidence, budgets and capital availability across the biotech and pharma landscape.When funding conditions tighten, even capable drug developers may delay projects, reduce outsourced work or scale back trial activity. That can hit revenue visibility for service businesses, regardless of the quality of the service provided.Against that backdrop, a strong first-half performance and confidence in a record year carry added significance. They suggest not just resilience, but possible operational momentum.The share price has improved too, but that is not the whole storyAlongside the operational improvement, Physiomics' share price has also seen a notable rebound, rising by around 66% year to date at the time of discussion.In ordinary circumstances, that would probably be taken as a clear signal that sentiment around the company is improving. But the picture is complicated by corporate governance developments, namely a requisition notice from activist shareholder Mike Whitlow.That requisition has created a situation where improving business performance is happening at the same time as a challenge to the current board.So while there may be genuine momentum in the underlying business, there is also uncertainty about who should be steering it.What the requisition notice meansThe requisition notice would, if passed, replace the current board with a new board.Management's position is clear: it does not believe that outcome would be in the best interests of the company.The immediate practical consequence is that shareholders have been asked to vote at a general meeting. The chairman's strongest message on this point is simple and democratic: shareholders should vote.Whatever position an investor takes, the emphasis is on participation. This is being framed not as a routine procedural matter, but as a genuinely consequential decision about the company's future direction and governance.That is an important distinction. Boardroom disputes can sometimes appear remote or technical. Here, the argument is that the vote could materially affect how the company is run at a delicate stage in its development.Why management says this is the wrong time to “rock the boat”The timing is at the centre of the board's response.The current leadership's view is that this challenge is arriving just as the company is beginning to show evidence of a turnaround. In other words, if the business is finally moving towards stronger revenue and a better trajectory, this may be precisely the wrong moment to disrupt leadership and strategy.That argument rests on a few connected ideas: The company appears to be improving operationally Recent results suggest traction rather than stagnation Change at board level introduces uncertainty Uncertainty can be especially damaging when a business is at a sensitive inflection point The phrase “rock the boat” captures the concern neatly. A business that has spent years navigating a difficult market and is now seeing signs of recovery may not benefit from abrupt upheaval, particularly if the alternative leadership has not set out a clear and credible plan.The board's objections to the proposed replacement directorsManagement's opposition is not based only on timing. It has also raised several specific concerns about the individuals named in the requisition notice.1. Lack of clearly relevant life sciences services experienceOne criticism is that the proposed directors do not appear, from the current board's perspective, to have the right experience in life sciences services.That point matters because Physiomics operates in a specialist technical area. This is not a generic consultancy business. It works at the intersection of mathematical modelling, clinical development and biostatistics. Running such a company effectively may require sector-specific understanding, not just general boardroom experience.2. No clear plan has been presentedAnother issue is the lack of an articulated strategy.The current board says it has seen no evidence of a plan, not even at a high level, explaining what the replacement board would actually do with the company.That absence of detail is central to the concern. Replacing a board is one thing. Explaining the strategy that would follow is another. Without that second piece, shareholders are effectively being asked to back change without a roadmap.3. Concerns about independenceThe board has also highlighted governance concerns. Specifically, it says the proposed individuals are all connected parties in some way, either through previous or current working relationships.From a governance standpoint, that raises the question of board independence. Best practice generally favours having independent directors who can challenge each other, think autonomously and avoid groupthink.If all proposed appointees are closely connected, the argument is that this could weaken the balance and independence expected of a well-run board.The central problem: shareholders are being asked to choose without enough detailPerhaps the most striking concern is also the simplest one: nobody really knows what the incoming group would do if it took control.That uncertainty sits at the heart of management's case against the requisition. The issue is not merely whether change is good or bad in principle. It is whether shareholders should support a board replacement when the intended strategy has not been laid out.As framed by the current leadership, that creates an asymmetrical choice: Option one: keep the existing board in place while the business appears to be improving Option two: replace the board with a group that has not communicated a clear plan From that perspective, the proposed change looks less like a defined alternative and more like a leap into the unknown.That is really the essence of the argument.Could the new group still have good intentions?To be fair, the current board has not claimed that the requisitioning group intends to damage the company. In fact, the stated hope is that they are interested because they see real potential in Physiomics and want to continue building on the progress already made.But hope is not the same as certainty.Without a clearly stated strategy, the board's position is that shareholders are being asked to make a consequential decision based on assumptions rather than evidence. And in a listed company, particularly one operating in a specialist and commercially sensitive field, that may not be enough.What shareholders are being asked to doThe practical takeaway is very clear. Shareholders are being urged to participate in the vote at the general meeting.The board's formal recommendation is that the resolutions should be rejected. But beyond that recommendation, there is a broader appeal to engagement. This is being presented as one of those moments when shareholders can directly influence the direction of the company.The message is not complicated: Read the information available Consider the company's recent progress Assess the risks around the proposed board changes Vote In governance terms, that is the crux of it. A listed company only functions properly when shareholders take an active interest in major decisions, especially when those decisions concern leadership, strategy and accountability.The bigger picture for PhysiomicsStrip away the corporate drama, and the underlying story is a relatively straightforward one.Physiomics is a specialist life sciences consultancy working in mathematical modelling and biostatistics for drug development. It has come through a difficult period for the wider life sciences sector and is now reporting stronger financial performance, with signs that it could deliver a record year.At exactly that moment, it faces an activist-led attempt to replace the board.Management's view is that this is the wrong intervention at the wrong time. The company says it is making progress, the business environment is becoming more supportive, and a disruptive governance change without a clearly articulated alternative plan would introduce unnecessary risk.Whether shareholders agree is, of course, a matter for them. But the issues at stake are now clear: Business momentum Board stability Strategic clarity Governance quality Those are not side issues. They go to the heart of whether Physiomics can build on its recent progress and sustain the upward trajectory management believes is now underway.

Episode Overview In this episode, I speak with Anna Mosikian, a physician by training and Global Clinical Program Lead working at the intersection of clinical development and strategic marketing. Anna brings a powerful perspective on how clinical data translates into real-world value—bridging evidence generation, regulatory expectations, and commercial impact. We dive into what clinical leaders truly expect from statisticians and how statisticians can move from technical contributors to strategic partners. We explore what “good collaboration” really looks like in practice, why understanding the purpose of a study is critical, and how statisticians can elevate their impact through communication, proactiveness, and cross-functional thinking.

Can identifying the right patients and the right endpoints transform how we test new osteoarthritis treatments? On this week's episode of Joint Action, we unpack what the FNIH Biomarkers Consortium has learned so far, and how their latest phase aims to deliver biomarkers that can make disease-modifying OA drug trials smaller, faster, and more likely to succeed.Dr. Virginia Byers Kraus is a Professor of Medicine, Pathology, and Orthopaedic Surgery at Duke University School of Medicine. A rheumatologist and translational scientist, her research focuses on osteoarthritis and biomarker development as part of the international FNIH Biomarkers Consortium.Peter G. Mesenbrink, Ph.D., is Executive Director of Biostatistics at Novartis and industry co-chair of the FNIH Biomarkers Consortium. With expertise in adaptive trial design, surrogate endpoint development, and data sharing policy, he is a frequent collaborator across industry, regulatory, and academic communities.Dr. Jamie Collins is a biostatistician at Brigham and Women's Hospital and Associate Professor of Orthopaedic Surgery at Harvard Medical School. As lead statistician for the FNIH OA Biomarkers Consortium, her research focuses on strengthening osteoarthritis clinical trials through innovative trial design and prognostic enrichment.RESOURCESFNIH: Treatment Response Biomarkers for Disease Modifying Osteoarthritis Drugs (DMOADs)CONNECT WITH USNaia Health: https://www.naiahealth.com.au/st-leonards-hubJoin one of our trials https://www.osteoarthritisresearch.com.au/current-trialsInstagram: @ProfDavidHunterTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

With the arrival of spring, anticipation grows for the start of horse racing in the United States. The pinnacle of success in the sport is achieved by a horse that will win each leg of the Triple Crown, which includes the Kentucky Derby, the Preakness Stakes, and the Belmont Stakes. The excitement and anticipation of these three races are also associated with pre-race bookmaking and betting as well. But just how good are the bookmakers at setting the odds of victory? Do their favorites win, or will long shots emerge victorious? That's the topic on today's episode of Stats+Stories with guest Larry Kupper. Dr. Kupper is Emeritus Alumni Distinguished Professor of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill. His research interests included the development and application of Statistical Methods for public health studies, particularly environmental, occupational, and women's health, and quantifying health risks from exposure to environmental and workplace hazards.

In this episode, I sit down with Rachael Lawrance to dive into a topic that has become absolutely central to clinical research: patient-centered outcomes. When I first started as a statistician, I knew these measures existed—but I didn't really understand how they were developed, analyzed, or used in decision-making. That has changed dramatically over the years. Today, patient-reported outcomes (PROs) and the broader framework of clinical outcome assessments (COAs) play a key role in regulatory approvals, payer decisions, and how we demonstrate treatment value. Rachael brings deep expertise from her work at Adelphi Values and shares how these endpoints are developed, validated, and applied in practice. We also discuss how statisticians can contribute more effectively by understanding the science behind these measures—not just treating them as “just another scale.”

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Shanshan Wu from the Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory of Digestive Health, National Clinical Research Center for Digestive Disease, Beijing, China, and Professor Yuanjie Pang from Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://bit.ly/4rRJeUI).

Usama Bilal, Associate Professor of Epidemiology and Co-Director of the Urban Health CollaborativeEpidemiology and Biostatistics, Drexel University, Philadelphia

In this episode of Plugged In to Public Health, Lauren sits down with Dr. Amy Herring, Professor of Statistical Science and Dean of Natural Sciences at Duke University, to explore how biostatistics shapes real-world public health research. From her early interest in applying math to meaningful problems to her current work across a wide range of health topics, Dr. Herring shares what it really looks like to build a career at the intersection of data and impact. The conversation highlights how statisticians collaborate with scientists and clinicians to translate complex questions into usable evidence. Dr. Herring walks through examples from her work, including global health research on sepsis in Tanzania, where differences in patient populations challenged assumptions built from studies in the United States and Europe. These experiences reveal how context, culture, and data quality all influence the conclusions we draw. This episode also touches on what makes collaboration effective, why understanding how data are collected is just as important as analyzing them, and how the field of biostatistics is evolving as data become larger and more complex. For students and early-career professionals, Dr. Herring offers practical advice on staying curious, getting involved in real-world data collection, and finding meaning in work that is not always linear. Whether you are interested in data, global health, or interdisciplinary research, this episode offers a grounded look at how biostatistics helps answer some of public health's most challenging questions. A transcript of this episode will be available here soon. Have a question for our podcast crew or an idea for an episode? You can email them at CPH-GradAmbassador@uiowa.edu You can also support Plugged in to Public Health by sharing this episode and others with your friends, colleagues, and social networks. #publichealth #healthcare #biostatistics #statisticalscience #naturalscience #dukeuniversity #datacollection #globalhealth #research #iowacity

What separates strong clinical research from misleading conclusions? Often, it comes down to study design. In this episode of the Clinical Trial Podcast, Kunal Sampat sits down with Dr. Thomas Newman, Professor of Epidemiology and Biostatistics at UCSF and co-author of Designing Clinical Research, to break down how observational studies actually work. While randomized controlled trials are often considered the gold standard, observational studies are essential in many real-world settings. But they come with challenges including bias, confounding, and misinterpretation that can lead to flawed conclusions if not handled correctly. Dr. Newman shares a practical framework to help you design better studies, interpret results more critically, and build a stronger foundation in clinical research. In this episode, you'll learn: When observational studies are more appropriate than randomized trials A practical framework for designing observational research Key threats to validity: bias, confounding, and chance How to interpret associations vs. causal effects Strategies for dealing with confounders in analysis How to approach statistics with more clarity and confidence About the guest: Dr. Thomas Newman, MD, MPH, is a Professor of Epidemiology and Biostatistics at the University of California, San Francisco. His work focuses on applying epidemiologic methods to important clinical problems in child health, including neonatal jaundice, infections in newborns, and cholesterol screening. He is widely recognized for his contributions to clinical research education and is co-author of Designing Clinical Research and Evidence-Based Diagnosis. Why this episode matters: If you want to grow in clinical research, you need more than surface-level knowledge - you need to understand how studies are designed and where they can go wrong. This episode helps you think like a clinical researcher.

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Paola Sebastiani, Professor of Biostatistics at Tufts Clinical and Translational Science Institute. They explore what centenarians reveal about reaching 100, and why there's no single longevity gene.Paola explains that studies keep finding many small genetic effects, which makes polygenic risk scores hard to use for personal prediction. She says progress depends on bigger cohorts and new analyses that include structural DNA changes and mitochondrial DNA. She also grounds the hype: for people born in 1900, only 0.2% of men and about 1% of women reached 100.Healthspan sits at the center of the story. Paola ties exceptional aging to delayed disease, lower inflammation, and biomarker profiles that stay more youthful. She highlights diet as a realistic lever, with centenarians showing stable, balanced eating, steadier protein intake, and metabolite signals linked to vegetables and dark chocolate.  Guest-at-a-glance

In early January 2026, the U.S. Centers for Disease Control and Prevention announced changes to the childhood immunization schedules, reducing the number of vaccines recommended for children. This change led to the U.S. being an outlier in terms of required vaccines for children. One reason people express concern about vaccines is fear of adverse reactions. It may surprise many that there is a comprehensive system in place to monitor adverse outcomes, and this is the topic of this episode with guest Dr. Jeffrey Morris. Dr. Jeffrey Morris is the George S. Pepper Professor of Public Health and Preventative Medicine and Director Biostatistics Division, Department of Biostatistics, Epidemiology and Informatics at the Perelman School of Medicine University of Pennsylvania. He has been actively involved in scientific communication efforts on social media and with various media outlets. He is also a distinguished research fellow at the Annenberg Center for Public Policy.

Three hundred and thirty-two days, that was the international statistic of the year in 2020, as identified by the Royal Statistical Society. That was the length of time between scientists publishing the genetic sequence of COVID-19 on the 11th of January, and an effective vaccine being administered on the 8th of December. This vaccine was an integral part of the world's pandemic response. Vaccines aren't new. In a World Health Organization report describing the history of vaccines, Dr. Edward Jenner is credited with the world's first successful vaccine for smallpox in 1796. In the last 100 years, vaccines were developed for yellow fever, pertussis, polio, hepatitis B, measles, mumps, rubella, and more. Well, how do we know vaccines are safe and effective? Why do some people argue against using vaccines? That's the topic of this episode with guest Dr. Jeffery Morris. Dr. Jeffrey Morris is the George S. Pepper Professor of Public Health and Preventative Medicine and Director Biostatistics Division, Department of Biostatistics, Epidemiology and Informatics at the Perelman School of Medicine University of Pennsylvania. He has been actively involved in scientific communication efforts on social media and with various media outlets. He is also a distinguished research fellow at the Annenberg Center for Public Policy.

After moving through nine states, Aaron Caldwell chose Fayetteville as home—and started using his data skills to decode city finances and a key local bond. In this episode, his work on a modest South Fayetteville infill project, close collaboration with city staff, and a growing circle of locals working to make the city more resilient show what Strong Towns looks like through one resident's life. ADDITIONAL SHOW NOTES Aaron Caldwell (LinkedIn) Local Recommendations: Hammontree's Feed and Folly Maxine's Tap Room ‍Norm Van Eeden Petersman (LinkedIn) Do you know someone who would make for a great Bottom-Up Revolution guest? Let us know here.   This podcast is made possible by Strong Towns members. Thank you!

Dr. Lloyd Edwards is Professor and Chair of Biostatistics at the University of Alabama at Birmingham. Dr. Edwards has an extensive background in collaborating with researchers in a broad range of areas in biomedical research, including cardiovascular disease, cystic fibrosis, cancer, aging, pediatrics, and minority health. His primary area of applied statistical research relates to the analysis of longitudinal data. Specifically, his statistical research includes derivation of techniques for computation of power, control of Type I error, and measuring model fit in linear and generalized linear mixed models.

Rebecca Wilson, Katie Brickey, John Kolassa, Jocelyn Sendecki, Paul Faya, and Mahan Dastgiri discuss the 2025 ASA Biopharmaceutical Section Nonclinical Biostatistics Conference.

Tara Eicher is a postdoctoral research fellow in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. T. Eicher, J. Quackenbush, and A. Ne'eman. Challenging Claims of an Autism Epidemic — Misconceptions and a Path Forward. N Engl J Med 2026;394:313-315.

Overdiagnosis and Medical Decision Making with Dr. Kathleen KerrIn this episode of The Girl Doc Survival Guide, Dr. Kathleen Kerr, a Professor of Biostatistics at the University of Washington, discusses overdiagnosis and medical decision making. Dr. Kerr delves into how patients perceive mammogram results, the difference between overdiagnosis and overcalling, and the challenges pathologists face in diagnosing cancer. She also shares findings from her research on the influence of prior opinions on second diagnoses and the cognitive processes involved in interpreting pathology images. The discussion highlights the complexities and subjectivity in pathology diagnoses and the implications for patient care.00:00 Introduction and Guest Welcome00:33 Personal Anecdote on Mammograms01:25 Understanding Screening and Its Limitations02:24 Exploring Overdiagnosis05:59 Research on Dermatopathologists' Perceptions08:20 Second Opinions in Medical Decision Making12:26 Pathologists' Diagnostic Process15:42 Final Thoughts on Diagnostic Criteria

In this episode of The Rational Egoist, Michael Liebowitz speaks with Dr. Knut M. Wittkowski, a biostatistician and epidemiologist whose career has been grounded in data analysis, population-level disease dynamics, and research design.Dr. Wittkowski approaches the COVID pandemic not from politics or media narratives, but from statistical evidence and historical epidemiology. Drawing on decades of experience analysing infectious disease patterns, he challenges widely accepted assumptions about lockdowns, transmission dynamics, and public-health interventions. His focus throughout is on what the data actually show—rather than what policymakers, institutions, or commentators wished them to show.The discussion explores:How pandemics historically rise and fallThe difference between individual clinical outcomes and population-level effectsWhy certain interventions may have had unintended consequencesThe importance of distinguishing correlation from causation in public health policyHow fear and modelling assumptions can override empirical evidenceThis is a rigorous, analytical conversation that treats public health as a scientific discipline rather than a moral crusade—and asks hard questions about decision-making under uncertainty.About Dr. Knut M. WittkowskiDr. Knut M. Wittkowski holds a PhD in Biostatistics, with formal training in mathematical statistics and epidemiology in Germany. He served for roughly two decades as Head of Biostatistics, Epidemiology, and Research Design at Rockefeller University in New York.His work has focused on the statistical foundations of biomedical research, the interpretation of complex data sets, and the proper design of epidemiological studies. Throughout his career, Dr. Wittkowski has emphasised methodological rigour, empirical validation, and intellectual independence—particularly when scientific consensus becomes detached from data.About Michael Liebowitz – Host of The Rational EgoistMichael Liebowitz is the host of The Rational Egoist podcast, a philosopher, author, and political activist committed to the principles of reason, individualism, and rational self-interest. Deeply influenced by the philosophy of Ayn Rand, Michael uses his platform to challenge cultural dogma, expose moral contradictions, and defend the values that make human flourishing possible.His journey from a 25-year prison sentence to becoming a respected voice in the libertarian and Objectivist communities is a testament to the transformative power of philosophy. Today, Michael speaks, writes, and debates passionately in defence of individual rights and intellectual clarity.He is the co-author of two books examining the failures of the correctional system and the redemptive power of moral conviction:Down the Rabbit Hole: How the Culture of Corrections Encourages Crimehttps://www.amazon.com.au/Down-Rabbit-Hole-Corrections-Encourages/dp/197448064XView from a Cage: From Convict to Crusader for Libertyhttps://books2read.com/u/4jN6xjAbout Xenia Ioannou – Producer of The Rational EgoistXenia Ioannou is the producer of The Rational Egoist, responsible for overseeing the publishing, presentation, and promotion of each episode to ensure a consistent standard of clarity, professionalism, and intellectual rigour.She is the CEO of Alexa Real Estate, a property manager and entrepreneur, and serves on the Board of Directors of the Ayn Rand Centre Australia. Xenia also leads Capitalism and Coffee in Adelaide, creating a forum for thoughtful discussion on philosophy, culture, and independent thinking.Join Capitalism and Coffee here:https://www.meetup.com/adelaide-ayn-rand-meetup/Follow Xenia's essays on reason, independence, and purposeful living at her Substack:https://substack.com/@xeniaioannou?utm_source=user-menuBecause freedom is worth thinking about — and talking about.#TheRationalEgoist

Lawrence M. Schell is a Distinguished Professor in the Department of Anthropology and the College of Integrated Health Sciences at the University at Albany, SUNY, with a joint appointment in the Department of Epidemiology and Biostatistics. His research explores the interrelationship between biology and culture, with a particular focus on how contemporary urban environments shape human health and development. Dr. Schell's early work examined noise as a form of urban stress, investigating its effects on prenatal and postnatal growth. He later expanded his research to include pollutants such as polychlorinated biphenyls (PCBs) and lead, situating these exposures within the broader context of urban adaptation and health disparities. The study of lead exposure in Albany, NY, examined its influence on child physical and cognitive development, with attention to maternal nutrition and other factors that affect the transfer of lead from mother to fetus. In partnership with the Akwesasne Mohawk Nation he has recently completed three major projects. The first examined how PCBs that were used in manufacturing affect physical and sexual development during adolescence. His second project followed up the adolescents in project 1 to learn how exposure had influenced their transition into adulthood. The third project, also conducted with the Akwesasne community, explored how environmental pollutants may impact reproductive health and fertility among women. Through this work, Dr. Schell highlights the urban environment as a critical frontier for human adaptation, emphasizing the challenges posed by pollution, stress, and other features of modern city life while recognizing that these challenges are inequitably distributed in society. In 2004 Schell established a research center at Albany with NIH support to grow research on health disparities. Continued NIH support culminated in an endowment grant that will support the center and the development of health disparities research for many years to come. ------------------------------ Contact the Sausage of Science Podcast and the Human Biology Association: Facebook: facebook.com/groups/humanbiologyassociation/, Website: humbio.org, Twitter: @HumBioAssoc Chris Lynn, Co-Host Website: cdlynn.people.ua.edu/, E-mail: cdlynn@ua.edu, Twitter:@Chris_Ly Courtney Manthey, Guest-Co-Host, Website: holylaetoli.com/ E-mail: cpierce4@uccs.edu, Twitter: @HolyLaetoli Anahi Ruderman, SoS Co-Producer, HBA Junior Fellow, E-mail: ruderman@cenpat-conicet.gob.ar

Last week attempts at cloud seeding to reduce pollution in Delhi failed to produce any rain. We catch up with reporter Chhavi Sachdev to find out more about official's latest and controversial attempt at tacking hazardous levels of air pollution in the city. The Maldives have become the first country to ban smoking for younger generations with no one born on or after 1 January 2007 being able to buy tobacco products. Journalist Philippa Roxby comments on what this means for health.What do the public know about the cancer risks of alcohol? Dr Sanjay Shete, Professor of Biostatistics and Epidemiology at the University of Texas, explains his research comparing the real risks to public awareness.A Finnish study has found that voting behaviours in elections are strongly linked to health, suggesting it may even be a stronger determinant than education. Plus, how walking over 5,000 steps a day may slow the cognitive decline in those with preclinical Alzheimer's disease.Presenter: Claudia Hammond Producer: Katie Tomsett & Hannah RobinsImage: A commuter walks near India Gate amid heavy smog pollution on October 29, 2025 in New Delhi, India. Delhi is once again blanketed by hazardous smog following the Diwali festival, as pollution levels spike to the "very poor" and "severe" categories, with air quality indexes far exceeding safe limits. The crisis, which is driven by firecracker use, emissions, and seasonal crop residue burning has prompted emergency measures like cloud seeding. Image Credit: Ritesh Shukla/Getty Images

In this podcast, JPEN Editor-in-Chief Dr. Kenneth Christopher, interviews Carly Milliren from the Biostatistics and Research Design Center at Boston Children's Hospital. Carly Milliren is a health services researcher primarily in pediatrics with a specific focus on eating disorders. Carly Milliren is first author of the research article “Identifying enteral nutrition using administrative data in pediatrics patients with eating disorders: A development and validation study”. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US October 2025

This year's Nobel Prize in Physiology or Medicine has been awarded for discoveries that explain how the immune system attacks hostile infections, but not the body's own cells. We explain the science that won Japan's Shimon Sakaguchi and US researchers Mary Brunkow and Fred Ramsdell the prestigious award.How robots can help children with reading anxiety. Lauren Wright from the University of Chicago who led this research explains.A new targeted antibiotic has been found that treats Inflammatory Bowel Disease. Dr Graham Easton who is Professor of Clinical Communication Skills at Queen Mary University of London describes how it works.Missing your first mammogram appointment has as much impact on breast cancer outcomes than an inherited genetic risk according to new research. Ziyan Ma from the Department of Medical Epidemiology and Biostatistics at the Karolinska Institute tells us more.And should we reconsider how we treat blood pressure? Presenter: Claudia Hammond Producer: Katie Tomsett

In this episode, we speak with Dr. Melody Goodman, Dean of NYU's School of Global Public Health, Professor of Biostatistics and a leading research methodologist. Dean Goodman shares her inspiring journey from a career on Wall Street to finding her passion for biostatistics and her purpose at NYU, showcasing the many paths that lead to public health leadership. As a biostatistician, she discusses the power of data to create a narrative and highlights how her commitment to solving community problems directly informs her work at GPH. We delve into her unique, hands-on approach to research, focused on community engagement and ensuring equitable outcomes. The episode also highlights the exceptional student experience at NYU GPH. Dean Goodman shares her philosophy on empowering and mentoring students. Her commitment to working alongside students on projects is a powerful testament to the collaborative and supportive environment that defines an education at NYU GPH. To learn more about the NYU School of Global Public Health, and how our innovative programs are training the next generation of public health leaders, visit http://www.publichealth.nyu.edu. 

About this episode: Does acetaminophen use during pregnancy cause autism in children? In this episode: Brian Lee, who led the largest study on acetaminophen use and neurodevelopmental outcomes, walks through the study's findings—as well as the challenges of researching the causal effects of medication use during pregnancy. Then, biostatistician Elizabeth Stuart discusses how she thinks about assessing potential cause-and-effect relationships when studies have different strengths and weaknesses. Guest: Brian Lee, PhD, MHS, is a professor of epidemiology and biostatistics at the Dornsife School of Public Health at Drexel University.   Elizabeth Stuart, PhD, is Chair in the Department of Biostatistics at the Johns Hopkins Bloomberg School of Public Health, where she focuses on designing and interpreting studies exploring causal effects. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability—JAMA What the evidence tells us about Tylenol, leucovorin, and autism—STAT Discovering How Environment Affects Autism—Hopkins Bloomberg Public Health Magazine Does A Really Cause B? How a Biostatistician Thinks About Causality—Public Health On Call (August 2024) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Send us a textCreate Your Causal Inference Roadmap. Causal Inference, TMLE & SensitivityIf you're into causal inference and machine learning you probably heard about double machine learning (DML).DML is one of the most popular frameworks leveraging machine learning algorithms for causal inference, while offering good statistical properties.Yet...There's another framework that also leverages machine learning for causal inference that was created years earlier.Welcome to the world of targeted maximum likelihood estimation (TMLE).Our today's guest, Prof. Mark van der Laan (UC Berkeley) is the godfather of TMLE.In the episode, we discuss:- Similarities and differences between DML and TMLE- How to build a causal roadmap for your project- How Mark uses math to solve real-world problems- Why uncertainty quantification is so important------------------------------------------------------------------------------------------------------Video version available on the Youtube: https://youtu.be/qr5JolEAuJURecorded on Sep 16, 2025 in Berkeley, California, US.------------------------------------------------------------------------------------------------------*About The Guest*Mark van der Laan is a Professor in Biostatistics and Statistics at UC Berkeley. He's the godfather of Targeted Maximum Likelihood Estimation (TMLE), a semiparametric framework that uses machine learning to estimate causal effects or other statistical parameters from observational data, and its new incarnation Targeted Machine Learning.*About The Host*Aleksander (Alex) Molak is an independent machine learning researcher, educator, entrepreneur and a best-selling author in the area of causality (https://amzn.to/3QhsRz4 ).Connect with Alex:- Alex on the Internet: https://bit.ly/aleksander-molak*Links*Libraries- Deep LTMLE (Python): https://github.com/shirakawatoru/dltmlePapers- Dang, ..., van der Laan et al. (2023) - "A Causal Roadmap for Generating High-Quality Real-World Evidence" (https://arxiv.org/abs/2305.06850)- Gruber, ..., van der Laan (2021) - "Developing a Targeted Learning-Based Statistical AnalysisSupport the showCausal Bandits PodcastCausal AI || Causal Machine Learning || Causal Inference & DiscoveryWeb: https://causalbanditspodcast.comConnect on LinkedIn: https://www.linkedin.com/in/aleksandermolak/Join Causal Python Weekly: https://causalpython.io The Causal Book: https://amzn.to/3QhsRz4

In a time where we need hope and innovation more than ever, we asked 13 health leaders—all guests on this podcast—what they would do to reimagine health. Tune into the episode to hear what they shared (in order of appearance):David Zipper, Senior Fellow, MIT Mobility Initiative Maya Petersen, Professor of Biostatistics, Epidemiology and Computational Precision Health, UC Berkeley Kody Kinsley, Senior Policy Advisor, Johns Hopkins University (former Secretary of HHS in North Carolina)Theresa Cullen, Director of Public Health, Pima County, AZ Anne Zink, Lecturer & Senior Fellow, Yale School of Public Health (former Chief Medical Officer, AlaskaKaren DeSalvo, former Chief Health Officer, Google Palav Babaria, Chief Quality and Medical Officer, California Department of Health Care Services Jacey Cooper, President, Precision Health Strategies (former Medicaid Director in California)Pooja Mittal, Chief Health Equity Officer, Health NetNatalie Davis, Co-Founder and CEO, United States of CareSteve Downs, Co-Founder, Building H Katie Drasser, CEO, Rock HealthZoanne Clack, Executive Producer, Grey's Anatomy Connect With UsFor more information on The Other 80 please visit our website - www.theother80.com. To connect with our team, please email claudia@theother80.com and follow us on twitter @claudiawilliams and LinkedInSubscribe to The Other 80 on YouTube so you never miss our video extras or special video episodes.

Welcome back to Dr. M's Women and Children First podcast where we look at the world of Women and Children's Health through an anthropological lens with the humble understanding that we have a lot to learn. Today, I'm joined by Dr. Joel “Dr. Gator” Warsh, a pediatrician, author, and advocate for a whole-child approach to healthcare. Dr. Warsh earned his medical degree from Thomas Jefferson Medical College and completed his pediatric residency at Children's Hospital of Los Angeles. Along the way, he also obtained a Master's degree in Epidemiology and Biostatistics from Queen's University in Canada, giving him a strong foundation in both clinical care and population health. These educational pursuits make him uniquely suited for today's conversation on vaccines. He is the author of Between a Shot and a Hard Place. In his own words, he says: I've dedicated my career to helping families navigate complicated health topics with clarity. My book addresses vaccine questions in a calm, data-driven, and practical way, offering parents guidance that steers clear of extremes. Parents face unprecedented pressure to make the "right" choices, often without enough balanced information. He has been featured on major platforms sharing his message with more than 400,000 parents through social media. We discuss his passion for empowering families to make informed, individualized decisions, including in areas that have been challenging or even taboo to discuss. Today, we'll dive into his latest work, his perspectives on vaccines and preventative care, and how he envisions a future of pediatrics that is proactive rather than reactive. This is a conversation about rethinking the foundations of child health and it's one you won't want to miss. Enjoy, Dr. M

Vidcast:  https://www.instagram.com/p/DNd_g0dN0lg/The low calorie and restricted nutrient diets that many overweight and obese men are following have a significant chance of making them depressed.  The University of Toronto's Departments of Psychiatry and Biostatistics reviewed data from more than 28,000 US men gathered from 2007 to 2018.While calorie-restrictive diets were associated with a bump in depressive feelings as well as a decline in cognitive performance, nutrient-restrictive diets intensified this effect.  Both calorie and nutrient restrictions led to more significant and negative emotional effects in men compared with women.  Such effects did not occur in balanced diets that included omega-3 fatty acids and vitamin B12.So guys….. if you plan to embark on a weight loss program, be certain your diet includes essential nutrients.  One good way to do this is to seek the advice of a certified clinical nutritionist.https://www.sciencedaily.com/releases/2025/06/250607103056.htmhttps://nutrition.bmj.com/content/8/1/10#dieting #depression #cognition #men

In this special replay episode — the top 3 most downloaded of all time — I'm again joined by Stuart McGuire as we explore The Chimp Paradox by Professor Steve Peters. This book provides a simple yet powerful model for understanding how our brain works — and how it often works against us if we're not aware of it. Whether in meetings, under pressure, or dealing with self-doubt, understanding your inner “chimp” can help you manage emotions, lead with clarity, and avoid the traps that keep so many statisticians and scientists stuck. This episode remains a favorite because it strikes at the core of how we think, react, and lead — especially in high-stakes scientific and business environments.

If you've been in a high street pharmacy or supermarket recently, chances are you'll have seen home test kits for all sorts of indications; blood sugar level, vitamin deficiencies, thyroid function, and even some forms of cancer. A new series of article in The BMJ revealing serious concerns with the reliability of these home tests, and raises questions about their regulation. Jonathan Deeks, professor of Biostatistics at the University of Birmingham, joins us to discuss what these tests are, and how his team have rated their usability. Also this week, the sad death of a child in Liverpool from measles highlights the growing outbreak in the UK - and this may be one of the first times many doctors have come across the infection. Frances Dutton, GP at the Small Heath Medical Practice reminds us how to recognise the sign of the infection.   Reading list Direct-to-consumer self-tests sold in the UK in 2023 How to recognise and manage measles

00:08 — John Feffer is Director of Foreign Policy in Focus. 00:33 — Art Reingold is the Division Head of Epidemiology and Biostatistics at the UC Berkeley School of Public Health. The post Russia's War in Ukraine; Plus, Corona Calls appeared first on KPFA.

Emily Riederer is a Data Science Senior Manager at Credit Risk Modeling Capital One. Her website can be found here: https://www.emilyriederer.com/   Follow along on Bluesky: Emily: ‪@emilyriederer.bsky.social‬ Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social  

Margaret Janiczek is a biostatistician artist and printmaker, currently focused on copperplate etching. We go over her start in creating cozy watercolor robots, and discovery of printmaking at First Proof Press. Along the way we find out about community life drawing, philosophy and theater, and learning piano. Follow Margaret's work on Instagram and her web site. Check out First Proof Press in Brattleboro Vermont.

00:08 — Negar Mortazavi is a journalist, political commentator, and host of the Iran Podcast.  00:33 — Art Reingold is the Division Head of Epidemiology and Biostatistics at the UC Berkeley School of Public Health. The post Israel and Trump's War in Iran; Plus, Corona Calls appeared first on KPFA.

Carly Brantner is an assistant professor of Biostatistics & Bioinformatics at Duke University and Duke Clinical Research Institute. Resources from this episode: multicate: R package for estimating conditional average treatment effects across one or more studies using machine learning methods PCORnet® Front Door: Access point for potential investigators, patient groups, and other stakeholders to connect with PCORnet and get support for potential research studies Patient-Centered Outcomes Data Repository (PDOCR): De-identified data from 24 (and counting) PCORI-funded studies Follow along on Bluesky: Carly: @carlybrantner.bsky.social Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social  

Drs. Jeffrey Jensen and Johanna Richey welcome Dr. Najwa Javed to Dean's Chat! Dr. Javed is a board certified podiatrist and founder of E'MAR Italy. She holds a Bachelor of Science in Biochemistry and Ethno-Anthropology from the University of Oklahoma and she has a Masters of Public Health in Biostatistics and Clinical Research with honors from the University of North Texas Health Science Center. This episode is sponsored by Bako Diagnostics! Dr. Javad received her Doctorate of Podiatric Medicine from the College of Podiatric medicine with Samuel Merritt University and she completed her surgical residency training program through the VA Palo Alto conjunction with Stanford university consortium. Join us, as she discusses the inspiration from experiences with her grandmother's health they got her interested in medicine.   Dr. Javed is the managing partner and CEO of Silicon Valley Podiatry Group and she's also the founder of E'MAR Italy, a luxury footwear brand built with patent pending medical technology for the modern women. Tune in, as we discuss “all things podiatric medicine” for this special entrepreneur episode!  She is part of the Female Founder Collective, a network of businesses led by women, supporting women. Her company won FAST Company's World Changing ideas Award, the Paysafe Entreprenista Pitch Competition and has been featured in several media outlets! She was recently featured as a speaker at the Synergy OPEN Silicone Valley Forum talking about “Scaling while staying private.” She is the recipient of the Philip Gardner award for excellence in podiatric medicine and she brings unique expertise as both practicing physician as well as Silicon Valley founder, and entrepreneur.  We hope you enjoy! https://najwajaved.com/ https://shopemar.shop/ https://bmef.org/ https://www.apma.org/

Dr. Cynthia Bulik is a clinical psychologist and one of the world's leading experts on eating disorders. She is the Founding Director of the University of North Carolina Center of Excellence for Eating Disorders and also the founder director of the Centre for Eating Disorders Innovation at Karolinska Institutet in Stockholm, Sweden. Dr. Bulik is Distinguished Professor of Eating Disorders in the Department of Psychiatry at UNC, Professor of Nutrition in the Gillings School of Global Public Health, and Professor of Medical Epidemiology and Biostatistics at Karolinska Institute.  Dr Bulik has received numerous awards for her pioneering work, including Lifetime Achievement Awards from the National Eating Disorders Association, the Academy for Eating Disorders, and the International Society of Psychiatric Genetics. She has written over 750 scientific papers, and several books aimed at educating the public about eating disorders.  Currently, Dr. Bulik's focus  is in the reconceptualization of eating disorders as being a metabo-psychiatric diseases. Food Junkies is keen to explore this interest in how metabolic disease plays a role in disordered eating: can this construct be the  common ground to start to understand the muddy waters  between eating disorders and food addiction?  In This Episode, You'll Learn:

In this episode Lucy and Ellie dig into a recently publicized paper, "Vaccination and Neurodevelopmental Disorders: A Study of Nine-Year-Old Children Enrolled in Medicaid", which has gained attention after being promoted by RFK Jr. as evidence that vaccines cause autism.    Ellie breaks down her Substack critique of the study. Together, she and Lucy discuss the methodological flaws and what a better version of this study might look like.   Vaccination and Neurodevelopmental Disorders: A Study of Nine-Year-Old Children Enrolled in Medicaid: https://publichealthpolicyjournal.com/vaccination-and-neurodevelopmental-disorders-a-study-of-nine-year-old-children-enrolled-in-medicaid/ RFK Jr is promoting a new study claiming "vaccines cause autism" but it doesn't add up. Literally [Ellie's substack]: https://epiellie.substack.com/p/rfk-jr-is-promoting-a-new-study-claiming   Follow along on Bluesky: Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social  

Vincent Arel-Bundock is a professor at the Université de Montréal, where he studies comparative and international political economy. Vincent's website: https://arelbundock.com/ Vincent's book "Model to Meaning: How to Interpret Statistical Models With marginaleffects for R and Python": https://marginaleffects.com/     Follow along on Bluesky: Vincent: @vincentab.bsky.social Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social    

My fabulous guest this week, Dr. Audrey Schnell, and I found ourselves very aligned in the discussion of her work as a trailblazer in personal development and transformation. Specifically the potential for Humanity as a whole to move into a much more abundant, prosperous, and enjoyable era and for individuals to reach their full, magnificent ability. This is a theme throughout her work, Dr. Schnell is renowned for her deep expertise, she has spent decades empowering individuals to break through their barriers and unlock their full potential. Dr. Schnell can uniquely pinpoint the hidden roots of self-sabotage and offer transformative guidance that leads to profound, lasting change. On this guest episode, Dr. Schnell speaks with us from the comfort of her amazing off-grid home in West Virginia. She shares about her experience starting out in the field of Epidemiology and Biostatistics, studying why and how people change for over 40 years. She goes on to share how she got into the coaching business and how health and wealth together are the foundation of success, what self-sabotage really is and how to get out of your own way.Bio:Dr. Schnell has an M.A. in Clinical Psychology and a Ph.D. in Epidemiology and Biostatistics.  She has been studying why and how people change for over 40 years. Audrey Schnell enables her clients to end self sabotage, stop derailing themselves, master their emotions and reach their goals. She helps people see the blind spots that are costing them money and eliminate emotional triggers so they can reach their potential, create long-term client relationships, and even turn difficult clients into success stores. She has been a featured speaker at retreats, been a valued guest on numerous industry podcasts and founded 2 successful online summits that featured over 20 top-flight experts from the world of healing and peak performance. Audrey lives off the grid on 40 Acres in rural West Virginia with her husband and dogs. Email: audrey@audreyschnellphd.comWebsite: www.audreyschnell.comFacebook: Audrey Schnell Instagram : audreyschnellphdLinktree : https://linktr.ee/audreyschnellLinkedin :Audrey Schnellhttps://audreyschnell.kartra.com/calendar/ZoomwithAudrey* Women Waken Wednesdays will be held weekly on Wednesdays at 6pm PST starting in February! This is a virtual Women's group I'm holding for my beautiful listeners. I would love for you to join! Please contact me (IG or Email) for Zoom info!Donations To Women Waken To Support The Show Are Greatly Appreciated

Noah Greifer is a statistical consultant and programmer at Harvard University. Episode notes: WeightIt package: https://ngreifer.github.io/WeightIt/ MatchIt package: https://kosukeimai.github.io/MatchIt/ Noah's awesome Stack Exchange post: https://stats.stackexchange.com/a/544958 Follow along on Bluesky: Noah: @noahgreifer.bsky.social Ellie: @EpiEllie.bsky.social Lucy: @LucyStats.bsky.social

Lucy and Ellie chat about large language models, chat interfaces, and causal inference. Do LLMs Act as Repositories of Causal Knowledge?: https://arxiv.org/html/2412.10635v1 Follow along on Twitter: The American Journal of Epidemiology: @AmJEpi Ellie: @EpiEllie Lucy: @LucyStats

This episode is sponsored by: Set For LifeSet for Life Insurance helps doctors safeguard their future with True Own Occupational Disability Insurance. A single injury or illness can change everything, but the best physicians plan ahead. Protect your income and secure your future before life makes the choice for you. Your career deserves protection—act now at https://www.doctorpodcastnetwork.co/setforlife_____Burnout and distress are pervasive in medicine, but improving physician well-being requires more than just resilience training and pizza parties. In this episode, Dr. Colin West shares the latest research on physician burnout, highlighting how workplace culture significantly impacts well-being. He and Dr. Bradley Block discuss the flawed "just tough it out" mindset ingrained in medical training, the systemic factors that contribute to distress, and the importance of aligning work with meaning, values, and purpose (MVPs) to maintain fulfillment in a medical career.They also explore practical solutions for physicians in various practice settings, from small groups to large institutions, emphasizing how addressing inefficiencies and reducing administrative burdens can enhance both job satisfaction and patient care. The conversation covers the role of coaching, social connection, and leadership in fostering a healthier medical culture, offering valuable insights for individual physicians and healthcare leaders alike..Three Actionable Takeaways:Burnout is not an individual problem—it's systemic: While personal coping strategies help, real change requires addressing workplace inefficiencies, excessive administrative burdens, and leadership approaches.Well-being initiatives must go beyond surface-level fixes: Yoga and mindfulness have value, but true solutions require structural changes like reducing unnecessary tasks and fostering social connections.Investing in physician well-being benefits everyone: When doctors are supported, they perform better, stay in their jobs longer, and deliver higher-quality patient care. About the Show:The Physician's Guide to Doctoring covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for the real-world lessons we should have learned in med school!About the Guest:Dr. Colin P. West is a Professor of Medicine, Medical Education, and Biostatistics at Mayo Clinic, specializing in internal medicine. He earned his M.D. and Ph.D. in Biostatistics from the University of Iowa. Dr. West's research focuses on physician well-being, burnout, and evidence-based medicine. He has published over 200 peer-reviewed articles and co-chaired the 2019 National Academy of Medicine consensus study on clinician burnout.Website: https://www.mayo.edu/research/faculty/west-colin-p-m-d-ph-d/bio-00027800LinkedIn: https://www.linkedin.com/in/colin-west-57821b82/About the Host:Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts the Physician's Guide to Doctoring podcast, focusing on personal and professional development for physicians.Want to be a guest? Email Brad at brad@physiciansguidetodoctoring.com or visit www.physiciansguidetodoctoring.com to learn more!Socials:  @physiciansguidetodoctoring on Facebook  @physicianguidetodoctoring on YouTube  @physiciansguide on Instagram and Twitter Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance.